TipRanks
Advertisement
Advertisement

DE:PHGN Stock Latest News

Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38
RatingsPharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38
5d ago
PHAR
Pharming announces CEO Fabrice Chouraqui to step down
PremiumThe Fly
Pharming announces CEO Fabrice Chouraqui to step down
6d ago
PHAR
Pharming Group Installs Interim Co-CEOs as Board and CEO Part Ways Over Strategy
PremiumCompany Announcements
Pharming Group Installs Interim Co-CEOs as Board and CEO Part Ways Over Strategy
6d ago
Pharming Wins FDA Priority Review for Lower-Dose Joenja in Younger APDS Patients
PremiumCompany Announcements
Pharming Wins FDA Priority Review for Lower-Dose Joenja in Younger APDS Patients
10d ago
Pharming announces FDA acceptance, Priority review of sNDA for Joenja
PremiumThe Fly
Pharming announces FDA acceptance, Priority review of sNDA for Joenja
10d ago
PHAR
Pharming’s initial Phase 2 Leniolisib data ‘encouraging,’ says H.C. Wainwright
PremiumThe FlyPharming’s initial Phase 2 Leniolisib data ‘encouraging,’ says H.C. Wainwright
13d ago
PHAR
Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs
Premium
The Fly
Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs
13d ago
PHAR
Pharming posts positive Phase II data for leniolisib in rare immune disorders
Premium
Company Announcements
Pharming posts positive Phase II data for leniolisib in rare immune disorders
13d ago
Pharming wins FDA nod to extend Joenja use to younger APDS children
PremiumCompany Announcements
Pharming wins FDA nod to extend Joenja use to younger APDS children
24d ago
FDA approves Joenja tablets for children aged 4-11 with APDS
PremiumThe Fly
FDA approves Joenja tablets for children aged 4-11 with APDS
24d ago
PHAR
Pharming Group Steps Up Investor Outreach With September Conference Lineup
PremiumCompany Announcements
Pharming Group Steps Up Investor Outreach With September Conference Lineup
26d ago
Pharming launches Joenja in Japan, first market to treat APDS children from age four
PremiumCompany Announcements
Pharming launches Joenja in Japan, first market to treat APDS children from age four
2M ago
Pharming Group to Present at Canaccord Genuity Growth Conference
PremiumCompany AnnouncementsPharming Group to Present at Canaccord Genuity Growth Conference
2M ago
Pharming price target raised to $38 from $37 at Canaccord
Premium
The Fly
Pharming price target raised to $38 from $37 at Canaccord
2M ago
PHAR
Pharming Group Earnings Call: Growth Story Amid Pressure
Premium
Company Announcements
Pharming Group Earnings Call: Growth Story Amid Pressure
2M ago
Pharming cuts FY26 revenue view to $375M-$395M from $405M-$425M
PremiumThe Fly
Pharming cuts FY26 revenue view to $375M-$395M from $405M-$425M
2M ago
PHAR
Pharming reports Q2 EPS 2c, consensus 6c
PremiumThe Fly
Pharming reports Q2 EPS 2c, consensus 6c
2M ago
PHAR
Pharming trims 2026 revenue outlook as Joenja growth offsets RUCONEST pressure
PremiumCompany Announcements
Pharming trims 2026 revenue outlook as Joenja growth offsets RUCONEST pressure
2M ago
Buy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained
3M ago
PHAR
Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
PremiumRatingsPharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
3M ago
PHAR
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
Premium
Ratings
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
4M ago
PHAR
Pharming’s Joenja granted marketing authorization by European Commission
Premium
The Fly
Pharming’s Joenja granted marketing authorization by European Commission
5M ago
PHAR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >